When does the Levemir (insulin detemir) patent expire?
A precise “Levemir patent expiration date” depends on which jurisdiction and which specific patent is being referenced, because different patents (and different jurisdictions) can expire on different dates. Patent protection for branded biologics like insulin products is also commonly followed by additional layers such as regulatory exclusivities and patent term adjustments, so the first generic/biosimilar entry date may not match the end of the last patent.
What patents typically control when a generic or biosimilar Levemir can launch?
Even after the original filing date lapses, companies often rely on remaining “family” patents (formulation, dosing, manufacturing, devices, or use-related claims) to delay competition. Courts or patent offices can also change the effective timeline through litigation or rejections, meaning a single “expiration date” is not always meaningful without specifying the patent numbers and the country.
How can you find the exact Levemir patent expiration date you need (country + patent)?
To get an exact expiration date, you need at least:
- The country (for example, US vs EU vs UK vs Canada)
- Whether you mean the first patent that expires or the last one that still blocks launch
- The specific patent(s) or application family (including publication numbers or patent numbers)
With those inputs, the expiration date can be determined from the patent record for that jurisdiction.
If you tell me your country, I can narrow it to the relevant date(s)
If you share the country (e.g., United States) and whether you want the “first possible launch date” or “the last blocking patent expiry,” I can narrow down the specific expiration timing for Levemir accordingly.
Sources
No sources were provided with the prompt, so I can’t cite an authoritative Levemir patent expiration date.